Am J Psychiatry 159:561-566, April 2002
© 2002 American Psychiatric Association
Association of Diabetes Mellitus With Use of Atypical Neuroleptics in the Treatment of Schizophrenia
Michael J. Sernyak, M.D.,
Douglas L. Leslie, Ph.D.,
Renato D. Alarcon, M.D.,
Miklos F. Losonczy, M.D., Ph.D., and
Robert Rosenheck, M.D.
OBJECTIVE: The development of both type I and type II diabetes after initiation of some atypical neuroleptics has been reported, primarily in studies involving small series of patients. This study used administrative data from a large national sample of patients with a diagnosis of schizophrenia to compare the prevalence of diabetes mellitus in patients receiving prescriptions for atypical and typical neuroleptics. METHOD: All outpatients with schizophrenia treated with typical and atypical neuroleptics over 4 months in 1999 in the Veterans Health Administration of the Department of Veterans Affairs (VA) were included in this study. Patients treated with atypical neuroleptics were those who received prescriptions for clozapine, olanzapine, risperidone, or quetiapine. Patients with a diagnosis of diabetes were also identified by using ICD-9 codes in VA administrative databases. The prevalence of diabetes mellitus across age groups and among patients receiving prescriptions for different atypical neuroleptics was examined with multiple logistic regression. RESULTS: A total of 38,632 patients were included in the study: 15,984 (41.4%) received typical neuroleptics and 22,648 (58.6%) received any atypical neuroleptic (1,207 [5.3%] received clozapine; 10,970 [48.4%], olanzapine; 955 [4.2%], quetiapine; and 9,903 [43.7%], risperidone; 387 patients received prescriptions for more than one atypical neuroleptic). When the effects of age were controlled, patients who received atypical neuroleptics were 9% more likely to have diabetes than those who received typical neuroleptics, and the prevalence of diabetes was significantly increased for patients who received clozapine, olanzapine, and quetiapine, but not risperidone. However, for patients less than 40 years old, all of the atypical neuroleptics were associated with a significantly increased prevalence of diabetes. CONCLUSIONS: In this large group of patients with schizophrenia, receipt of a prescription for atypical neuroleptics was significantly associated with diabetes mellitus.
This article has been cited by other articles:
|
|
|
|
 
F. Andersohn, R. Schade, S. Suissa, and E. Garbe
Long-Term Use of Antidepressants for Depressive Disorders and the Risk of Diabetes Mellitus
Am J Psychiatry,
May 1, 2009;
166(5):
591 - 598.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Sentissi, J. Epelbaum, J.-P. Olie, and M.-F. Poirier
Leptin and Ghrelin Levels in Patients With Schizophrenia During Different Antipsychotics Treatment: A Review
Schizophr Bull,
November 1, 2008;
34(6):
1189 - 1199.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Hammerman, J. Dreiher, S. H Klang, H. Munitz, A. D Cohen, and M. Goldfracht
Antipsychotics and Diabetes: An Age-Related Association
Ann. Pharmacother.,
September 1, 2008;
42(9):
1316 - 1322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Smith, D. Hopkins, R. C. Peveler, R. I. G. Holt, M. Woodward, and K. Ismail
First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis
The British Journal of Psychiatry,
June 1, 2008;
192(6):
406 - 411.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Sernyak and R. A. Rosenheck
Antipsychotic Use in the Treatment of Outpatients With Schizophrenia in the VA From Fiscal Years 1999 to 2006
Psychiatr Serv,
May 1, 2008;
59(5):
567 - 569.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Dickinson, J. M. Gold, F. B. Dickerson, D. Medoff, and L. B. Dixon
Evidence of Exacerbated Cognitive Deficits in Schizophrenia Patients With Comorbid Diabetes
Psychosomatics,
April 1, 2008;
49(2):
123 - 131.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. F. Buckley, A. Foster, and B. Miller
Schizophrenia Host Vulnerability and Risk of Metabolic Disturbances During Treatment with Antipsychotics
Focus,
April 1, 2008;
6(2):
172 - 179.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.A. Rosenheck, D.L. Leslie, S. Busch, E. S. Rofman, and M. Sernyak
Rethinking Antipsychotic Formulary Policy
Schizophr Bull,
March 1, 2008;
34(2):
375 - 380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Behroozi, G. Mazowita, and M. D. Davis
Collaboration in caring for psychiatric inpatients: Family physicians team up with psychiatrists and psychiatric nurses
Can Fam Physician,
January 1, 2008;
54(1):
57 - 57.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Olfson, S. C. Marcus, and H. Ascher-Svanum
Treatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or Risperidone
Schizophr Bull,
November 1, 2007;
33(6):
1379 - 1387.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Hippisley-Cox, C. Parker, C. Coupland, and Y. Vinogradova
Inequalities in the primary care of patients with coronary heart disease and serious mental health problems: a cross-sectional study
Heart,
October 1, 2007;
93(10):
1256 - 1262.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. L Citrome, R. I. Holt, W. M Zachry, J. D Clewell, P. A Orth, J. L Karagianis, and V. P. Hoffmann
Risk of Treatment-Emergent Diabetes Mellitus in Patients Receiving Antipsychotics
Ann. Pharmacother.,
October 1, 2007;
41(10):
1593 - 1603.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L Dufresne
Weighing In: Emergent Diabetes Mellitus and Second-Generation Antipsychotics
Ann. Pharmacother.,
October 1, 2007;
41(10):
1725 - 1727.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.H. Barnett, P. Mackin, I. Chaudhry, A. Farooqi, R. Gadsby, A. Heald, J. Hill, H. Millar, R. Peveler, A. Rees, et al.
Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia
J Psychopharmacol,
June 1, 2007;
21(4):
357 - 373.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. M. Noel
ASHP Therapeutic Position Statement on the Use of Second-Generation Antipsychotic Medications in the Treatment of Adults with Psychotic Disorders
Am. J. Health Syst. Pharm.,
April 15, 2007;
64(8):
863 - 876.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Chavez and R. A Poveda
Efficacy with High-Dose Aripiprazole After Olanzapine-Related Metabolic Disturbances
Ann. Pharmacother.,
December 1, 2006;
40(12):
2265 - 2268.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Burton
Symptom domains of schizophrenia: the role of atypical antipsychotic agents
J Psychopharmacol,
November 1, 2006;
20(6_suppl):
6 - 19.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. S Turner and D. W Stewart
Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses
J Psychopharmacol,
November 1, 2006;
20(6_suppl):
20 - 37.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Chue
The relationship between patient satisfaction and treatment outcomes in schizophrenia
J Psychopharmacol,
November 1, 2006;
20(6_suppl):
38 - 56.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. L. Lambert, F. E. Cunningham, D. R. Miller, G. W. Dalack, and K. Hur
Diabetes Risk Associated with Use of Olanzapine, Quetiapine, and Risperidone in Veterans Health Administration Patients with Schizophrenia
Am. J. Epidemiol.,
October 1, 2006;
164(7):
672 - 681.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Krein, C. R. Bingham, J. F. McCarthy, A. Mitchinson, J. Payes, and M. Valenstein
Diabetes Treatment Among VA Patients With Comorbid Serious Mental Illness
Psychiatr Serv,
July 1, 2006;
57(7):
1016 - 1021.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. T. Bloomgarden
Atypical Antipsychotic Agents, Retinopathy, Nephropathy, and Cardiovascular Disease.
Diabetes Care,
June 1, 2006;
29(6):
1439 - 1446.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Weissman, D. M. Moot, and S. M. Essock
What Do People With Schizophrenia Think About Weight Management?
Psychiatr Serv,
May 1, 2006;
57(5):
724 - 725.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Bola
Psychosocial Acute Treatment in Early-Episode Schizophrenia Disorders
Research on Social Work Practice,
May 1, 2006;
16(3):
263 - 275.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Cohen, R. P. Stolk, D. E. Grobbee, and C. C. Gispen-de Wied
Hyperglycemia and Diabetes in Patients With Schizophrenia or Schizoaffective Disorders
Diabetes Care,
April 1, 2006;
29(4):
786 - 791.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Gianfrancesco, J. Pesa, R.-H. Wang, and H. Nasrallah
Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: Sensitivity to study design
Am. J. Health Syst. Pharm.,
March 1, 2006;
63(5):
431 - 441.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Llorente and V. Urrutia
Diabetes, Psychiatric Disorders, and the Metabolic Effects of Antipsychotic Medications
Clin. Diabetes,
January 1, 2006;
24(1):
18 - 24.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Hosojima, T. Togo, T. Odawara, K. Hasegawa, S. Miura, Y. Kato, A. Kanai, A. Kase, H. Uchikado, and Y. Hirayasu
Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia
J Psychopharmacol,
January 1, 2006;
20(1):
75 - 79.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Tighe and T. Dinan
An overview of the central control of weight regulation and the effect of antipsychotic medication
J Psychopharmacol,
November 1, 2005;
19(6_suppl):
36 - 46.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. I. G. Holt, C. Bushe, and L. Citrome
Diabetes and schizophrenia 2005: are we any closer to understanding the link?
J Psychopharmacol,
November 1, 2005;
19(6_suppl):
56 - 65.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. Freedman
The Choice of Antipsychotic Drugs for Schizophrenia
N. Engl. J. Med.,
September 22, 2005;
353(12):
1286 - 1288.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. J. Fedorowicz and E. Fombonne
Metabolic side effects of atypical antipsychotics in children: a literature review
J Psychopharmacol,
September 1, 2005;
19(5):
533 - 550.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. R. Richardson, G. Faulkner, J. McDevitt, G. S. Skrinar, D. S. Hutchinson, and J. D. Piette
Integrating Physical Activity Into Mental Health Services for Persons With Serious Mental Illness
Psychiatr Serv,
March 1, 2005;
56(3):
324 - 331.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Taylor, C. Young, R. Mohamed, C. Paton, and R. Walwyn
Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs
J Psychopharmacol,
March 1, 2005;
19(2):
182 - 186.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. A. Rosenheck
Open Forum: Effectiveness Versus Efficacy of Second-Generation Antipsychotics: Haloperidol Without Anticholinergics as a Comparator
Psychiatr Serv,
January 1, 2005;
56(1):
85 - 92.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. E. Davis, M. W. Becher, W. Tlomak, B. E. Benson, R. R. Lee, and E. C. Fisher
Persistent Choreoathetosis in a Fatal Olanzapine Overdose: Drug Kinetics, Neuroimaging, and Neuropathology
Am J Psychiatry,
January 1, 2005;
162(1):
28 - 33.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Henderson, E. Cagliero, P. M. Copeland, C. P. Borba, E. Evins, D. Hayden, M. T. Weber, E. J. Anderson, D. B. Allison, T. B. Daley, et al.
Glucose Metabolism in Patients With Schizophrenia Treated With Atypical Antipsychotic Agents: A Frequently Sampled Intravenous Glucose Tolerance Test and Minimal Model Analysis
Arch Gen Psychiatry,
January 1, 2005;
62(1):
19 - 28.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. B. Schur, L. Sikich, R. L. Findling, R. P. Malone, M. L. Crismon, A. Derivan, J. C. MacIntyre II, E. Pappadopulos, L. Greenhill, N. Schooler, et al.
Treatment Recommendations for the Use of Antipsychotics for Aggressive Youth (TRAAY), Part I: A Review
Focus,
October 1, 2004;
2(4):
596 - 607.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Rosenheck
Back to the Future: Funding, Integrating, and Improving Mental Health Services
Psychiatr Serv,
October 1, 2004;
55(10):
1141 - 1142.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Simpson, I. D. Glick, P. J. Weiden, S. J. Romano, and C. O. Siu
Randomized, Controlled, Double-Blind Multicenter Comparison of the Efficacy and Tolerability of Ziprasidone and Olanzapine in Acutely Ill Inpatients With Schizophrenia or Schizoaffective Disorder
Am J Psychiatry,
October 1, 2004;
161(10):
1837 - 1847.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Citrome, A. Jaffe, J. Levine, B. Allingham, and J. Robinson
Relationship Between Antipsychotic Medication Treatment and New Cases of Diabetes Among Psychiatric Inpatients
Psychiatr Serv,
September 1, 2004;
55(9):
1006 - 1013.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Akhtar, C. Kelly, A. Gallagher, and J. R Petrie
Review: Newer antipsychotic agents, carbohydrate metabolism and cardiovascular risk
The British Journal of Diabetes & Vascular Disease,
September 1, 2004;
4(5):
303 - 309.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. L. Leslie and R. A. Rosenheck
Incidence of Newly Diagnosed Diabetes Attributable to Atypical Antipsychotic Medications
Am J Psychiatry,
September 1, 2004;
161(9):
1709 - 1711.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. B. Dixon, J. A. Kreyenbuhl, F. B. Dickerson, T. W. Donner, C. H. Brown, K. Wolheiter, L. Postrado, R. W. Goldberg, L. Fang, C. Marano, et al.
A Comparison of Type 2 Diabetes Outcomes Among Persons With and Without Severe Mental Illnesses
Psychiatr Serv,
August 1, 2004;
55(8):
892 - 900.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. V. Seeman
Gender Differences in the Prescribing of Antipsychotic Drugs
Am J Psychiatry,
August 1, 2004;
161(8):
1324 - 1333.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Marder, S. M. Essock, A. L. Miller, R. W. Buchanan, D. E. Casey, J. M. Davis, J. M. Kane, J. A. Lieberman, N. R. Schooler, N. Covell, et al.
Physical Health Monitoring of Patients With Schizophrenia
Am J Psychiatry,
August 1, 2004;
161(8):
1334 - 1349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Gentile
Clinical Utilization of Atypical Antipsychotics in Pregnancy and Lactation
Ann. Pharmacother.,
July 1, 2004;
38(7):
1265 - 1271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Vreeland and E. Kim
Managing the Clinical Consequences of Psychiatric Illness and Antipsychotic Treatment: A Discussion of Obesity, Diabetes, and Hyperprolactinemia
Journal of the American Psychiatric Nurses Association,
June 1, 2004;
10(3_suppl):
S17 - S24.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. K. Kaholokula, T. N. Schirmer, and D. Elting
Identifying and Prioritizing Diabetes Care Issues Among Mental Health Professionals of a Multi-Ethnic, State Psychiatric Hospital
Diabetes Spectr,
April 1, 2004;
17(2):
123 - 128.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bushe and R. Holt
Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia
The British Journal of Psychiatry,
April 1, 2004;
184(47):
s67 - s71.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Thakore
Metabolic disturbance in first-episode schizophrenia
The British Journal of Psychiatry,
April 1, 2004;
184(47):
s76 - s79.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Haddad
Antipsychotics and diabetes: review of non-prospective data
The British Journal of Psychiatry,
April 1, 2004;
184(47):
s80 - s86.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bushe and B. Leonard
Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data
The British Journal of Psychiatry,
April 1, 2004;
184(47):
s87 - s93.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Cavazzoni, N. Mukhopadhyay, C. Carlson, A. Breier, and J. Buse
Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications
The British Journal of Psychiatry,
April 1, 2004;
184(47):
s94 - s101.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Peet
Diet, diabetes and schizophrenia: review and hypothesis
The British Journal of Psychiatry,
April 1, 2004;
184(47):
s102 - s105.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Gough and R. Peveler
Diabetes and its prevention: pragmatic solutions for people with schizophrenia
The British Journal of Psychiatry,
April 1, 2004;
184(47):
s106 - s111.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. D. Howes, A. Bhatnagar, F. P. Gaughran, S. A. Amiel, R. M. Murray, and L. S. Pilowsky
A Prospective Study of Impairment in Glucose Control Caused by Clozapine Without Changes in Insulin Resistance
Am J Psychiatry,
February 1, 2004;
161(2):
361 - 363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes
Diabetes Care,
February 1, 2004;
27(2):
596 - 601.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. L Citrome and A. B Jaffe
Relationship of Atypical Antipsychotics with Development of Diabetes Mellitus
Ann. Pharmacother.,
December 1, 2003;
37(12):
1849 - 1857.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Rosenheck, D. Perlick, S. Bingham, W. Liu-Mares, J. Collins, S. Warren, D. Leslie, E. Allan, E. C. Campbell, S. Caroff, et al.
Effectiveness and Cost of Olanzapine and Haloperidol in the Treatment of Schizophrenia: A Randomized Controlled Trial
JAMA,
November 26, 2003;
290(20):
2693 - 2702.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hardy and A. Breier
Patients on Atypical Antipsychotic Drugs: Another High-Risk Group for Type 2 Diabetes: Response to Lean and Pajonk
Diabetes Care,
November 1, 2003;
26(11):
3200 - 3201.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Freedman
Schizophrenia
N. Engl. J. Med.,
October 30, 2003;
349(18):
1738 - 1749.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Copeland, J. E. Zeber, M. Valenstein, and F. C. Blow
Racial Disparity in the Use of Atypical Antipsychotic Medications Among Veterans
Am J Psychiatry,
October 1, 2003;
160(10):
1817 - 1822.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L D. Ried, B. T Renner, M. A Bengtson, B. M Wilcox, and W. W Acholonu Jr
Weight Change After an Atypical Antipsychotic Switch
Ann. Pharmacother.,
October 1, 2003;
37(10):
1381 - 1386.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. W. Smith and G. J. Joseph
Pharmacy Data in the VA Health Care System
Med Care Res Rev,
September 1, 2003;
60(3_suppl):
92S - 123S.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Rosack
New Studies Raise Questions About Antipsychotic Efficacy
Psychiatr News,
July 4, 2003;
38(13):
18 - 19.
[Full Text]
|
|
|
|
|
|
|
M. E.J. Lean and F.-G. Pajonk
Patients on Atypical Antipsychotic Drugs: Another high-risk group for type 2 diabetes
Diabetes Care,
May 1, 2003;
26(5):
1597 - 1605.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Doyle and J. M. Egan
Pharmacological Agents That Directly Modulate Insulin Secretion
Pharmacol. Rev.,
March 1, 2003;
55(1):
105 - 131.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. K. GELLER and W. MacFADDEN
Diabetes and Atypical Neuroleptics
Am J Psychiatry,
February 1, 2003;
160(2):
388 - 388.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. L. Daumit, R. M. Crum, E. Guallar, N. R. Powe, A. B. Primm, D. M. Steinwachs, and D. E. Ford
Outpatient Prescriptions for Atypical Antipsychotics for African Americans, Hispanics, and Whites in the United States
Arch Gen Psychiatry,
February 1, 2003;
60(2):
121 - 128.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. L Citrome
Efficacy should drive atypical antipsychotic treatment
BMJ,
February 1, 2003;
326(7383):
283 - 283.
[Full Text]
|
|
|
|
|
|
|
D. L. Leslie and R. A. Rosenheck
From Conventional to Atypical Antipsychotics and Back: Dynamic Processes in the Diffusion of New Medications
Am J Psychiatry,
September 1, 2002;
159(9):
1534 - 1540.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Atypical Antipsychotics May Be Associated with Diabetes Mellitus
Journal Watch Psychiatry,
May 8, 2002;
2002(508):
2 - 2.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2002
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
